HNGE stock forecast, quote, news & analysis
Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain... Show more
Why Hinge Health (HNGE) Stock Is Up +16.7% in the Last 30 Days
Key Takeaways
- Hinge Health (HNGE) climbed roughly 16.7% over the past 30 days, rising from about $95.57 to $111.52.
- The advance extends a broader rally, with shares up approximately 50% from their mid-July low near $74.
- Second-quarter results showing 53% year-over-year revenue growth to $212.8 million, coupled with raised full-year guidance, underpinned the move.
- Expansion into migraine and gastrointestinal care—including the roughly $105 million agreement to acquire Cylinder Health—widened the company's addressable market.
- Several analysts lifted price targets in October, including KeyBanc to $140 and BofA to $130.
- Third-quarter earnings, scheduled for November 2, 2026, represent the next key catalyst for the stock.
- For deeper detail on valuation and outlook, explore the ticker's Price Targets, Earnings, and Forecast pages.
- Investors can also explore Trending AI Robots for AI-driven trading signals across thousands of tickers.
Hinge Health (HNGE) Company Overview and Market Position
Hinge Health, Inc. is a San Francisco-based digital health company that uses software and artificial intelligence to automate care for joint and muscle health. Its TrueMotion platform addresses musculoskeletal (MSK) care across acute injury, chronic pain, and post-surgical rehabilitation, combining AI-powered motion tracking with the FDA-cleared Enso electrical nerve stimulation wearable and an AI-supported clinical care team of physical therapists, physicians, and health coaches.
The company primarily sells to self-insured employers and also partners with health plans, pharmacy benefit managers, and third-party administrators. Hinge Health went public on the New York Stock Exchange in May 2025 and has since expanded from MSK care into adjacent categories, including migraine and gastrointestinal care. Investors follow the stock for its rapid revenue growth, improving margins, and its role as a high-growth, AI-enabled software platform within the healthcare technology sector.
Hinge Health (HNGE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Hinge Health shares advanced approximately 16.7%, rising from a close near $95.57 to $111.52. The move was broad-based rather than a single-session spike, with the stock climbing through October as analyst price targets were revised higher and sentiment around AI-enabled healthcare software strengthened.
The 30-day gain is part of a longer uptrend. Over the last quarter, HNGE has risen roughly 50%, rebounding from a mid-July low near $74 and then extending higher after a strong second-quarter earnings report in early August. The stock's trend has been characterized by higher lows and a series of new highs as investors have repriced the company's growth and profitability trajectory.
What Drove HNGE Stock Price in the Last 30 Days
The recent advance was driven primarily by continued confidence in the company's growth and profitability, reinforced by a cluster of analyst actions. In October, KeyBanc raised its price target to $140 from $125 while maintaining an Overweight rating, and BofA raised its target to $130 from $110 while keeping a Buy rating. Barclays lifted its target to $110 from $100, RBC Capital maintained a Buy with a $110 target, and Morgan Stanley reiterated a $117 target.
Broader strategic news also supported sentiment. In early October, management signaled plans to pursue hardware-focused acquisitions to strengthen the Enso wearable and mobile app, building on the company's second-quarter results, which included 53% revenue growth, an adjusted gross margin of 87%, and raised full-year guidance. The expansion into migraine care—which grew to more than 450 clients—and the planned acquisition of Cylinder Health to enter gastrointestinal care underscored the platform's move beyond MSK into a multi-condition model. Some insider selling was reported during the period, but the overall trend remained firmly upward.
What Drove HNGE Stock Performance Over the Last Quarter
The roughly 50% gain over the last quarter reflects a sustained re-rating following Hinge Health's second-quarter report in early August. Revenue rose 53% year over year to $212.8 million, adjusted operating income climbed to $61.5 million, and management raised full-year revenue guidance to $856 million to $860 million and adjusted operating income guidance to $236 million to $244 million. The company also announced a $300 million share repurchase authorization and the Cylinder Health acquisition.
The larger narrative is one of operating leverage: as revenue scales, margins have expanded, and free cash flow has improved. Investors have increasingly treated Hinge Health as a category-defining, AI-enabled software platform rather than a niche MSK vendor, and analyst price targets across the Street have risen accordingly over the quarter.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that actively trade thousands of tickers, but only the top-performing and most relevant strategies appear in its curated Trending AI Robots section. These bots vary widely in strategy, timeframe, and performance metrics, giving traders a range of approaches for navigating different market conditions. The page is designed to help users quickly identify the AI signals and automated strategies currently generating the strongest results. For those seeking an additional, data-driven perspective on names like HNGE and the broader market, exploring this section can be a useful complement to fundamental research.
HNGE Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst is Hinge Health's third-quarter earnings report on November 2, 2026. Investors will focus on revenue growth, adjusted operating margin, membership and client additions, and whether guidance is raised again—particularly given elevated expectations following the second quarter.
Beyond earnings, key factors include the integration of Cylinder Health and the timing of the broader gastrointestinal care rollout expected in 2027, the pace of migraine care adoption, and any progress on hardware-focused acquisitions. Competitive pressure from broader digital health platforms such as Omada Health (OMDA) and Teladoc Health (TDOC) also bears watching, as does valuation, which has become a central point of debate given the stock's rapid appreciation. Macroeconomic conditions affecting employer healthcare budgets remain a relevant risk. This information is provided for educational purposes and should not be interpreted as a forecast or investment recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for HNGE shows an upward move is likely
HNGE's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 76 similar instances where the Aroon Indicator showed a similar pattern. In 67 of the 76 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where HNGE advanced for three days, in 82 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 11 of 15 cases where HNGE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HNGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
HNGE broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HNGE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HNGE's P/B Ratio (27.129) is slightly higher than the industry average of (4.477). P/E Ratio (14.015) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.504) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HNGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the difference between active and passive money management?
Will my target mutual funds miss their targets?
For a bright financial future, stay away from these 4 frequent traps.
What is the statistical significance of the median and how is it calculated?
What is Form 706: Estate Tax and Generation-Skipping Transfer Tax?
General Information
Industry ServicestotheHealthIndustry